{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Porter M"],"funding":["European & Developing Countries Clinical Trials Partnership (EDCTP)","NIAID NIH HHS","FIC NIH HHS","NHGRI NIH HHS","Wellcome Trust"],"pagination":["2920-2928.e5"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9952832"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["142(11)"],"pubmed_abstract":["Severe cutaneous adverse reactions related to first-line antituberculosis drugs are associated with high mortality and long-term morbidity. Oral sequential drug challenge, as a form of drug provocation testing, helps to salvage therapy by identifying culprit drugs but is associated with risk and is costly. IFN-γ enzyme-linked immune absorbent spot (ELISpot), an adjunctive in vitro diagnostic tool, may help to guide risk-stratification approaches. To determine the diagnostic accuracy of IFN-γ ELISpot against full-dose sequential drug challenge, we analyzed samples collected prospectively at multiple time points in 32 patients with first-line antituberculosis drug‒associated severe cutaneous adverse reaction (81% HIV infected, 25 with drug reaction with eosinophilia and systemic symptoms, an"],"journal":["The Journal of investigative dermatology"],"pubmed_title":["IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting."],"pmcid":["PMC9952832"],"funding_grant_id":["214321/Z/18/Z","TMA2017SF-1981","U01 AI154659","R01 HG010863","K43 TW011178","R01 AI152183","UM1 AI109565","D43 TW010559","203135/Z/16/Z"],"pubmed_authors":["Phillips E","Smith R","Porter M","Peter J","Pedretti S","Chimbetete T","Lehloenya R","Choshi P","Meintjes G"],"additional_accession":[]},"is_claimable":false,"name":"IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting.","description":"Severe cutaneous adverse reactions related to first-line antituberculosis drugs are associated with high mortality and long-term morbidity. Oral sequential drug challenge, as a form of drug provocation testing, helps to salvage therapy by identifying culprit drugs but is associated with risk and is costly. IFN-γ enzyme-linked immune absorbent spot (ELISpot), an adjunctive in vitro diagnostic tool, may help to guide risk-stratification approaches. To determine the diagnostic accuracy of IFN-γ ELISpot against full-dose sequential drug challenge, we analyzed samples collected prospectively at multiple time points in 32 patients with first-line antituberculosis drug‒associated severe cutaneous adverse reaction (81% HIV infected, 25 with drug reaction with eosinophilia and systemic symptoms, an","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T00:04:05.147Z","creation":"2025-04-04T00:04:05.147Z"},"accession":"S-EPMC9952832","cross_references":{"pubmed":["35659939"],"doi":["10.1016/j.jid.2022.05.1059"]}}